SeqOne Acquires Congenica to Lead AI Genomic Medicine

– Strategic acquisition of UK genomics chief Congenica reinforces SeqOne market place and footprint – servicing over 160 labs in 30+ international locations

– The acquisition creates the biggest international ‘software program pure participant’ within the scientific genomics house, which can keep UK presence on the famend Wellcome Sanger Institute

SeqOne, a pioneer in AI-driven genomic evaluation, as we speak introduced it has entered right into a definitive settlement to accumulate Congenica, the UK firm spun out of the distinguished Wellcome Sanger Institute. The acquisition creates the biggest international ‘software program pure participant’ within the genomics house, serving over 160 labs in additional than 30 international locations.

Based in 2012, Congenica brings a legacy of deep scientific experience and expertise servicing over 25 non-public and public labs, together with a number of NHS Genomics Laboratory Hubs and prestigious nationwide applications comparable to Genomics England and the Hong Kong Genomic Program.

SeqOne is an AI-powered genomic evaluation platform, offering scientific decision-support instruments that allow molecular laboratories to ship quick, correct, and scalable evaluation of genetic information for purposes in oncology, uncommon and inherited illnesses, and infectious illnesses.

The acquisition unites SeqOne’s AI-powered platform for Subsequent-Technology Sequencing (NGS) evaluation with Congenica’s trusted scientific resolution help expertise and scientific interpretation companies. The built-in providing will remodel complicated genomic information into fast, actionable insights, in the end accelerating prognosis for households affected by uncommon illness and enabling extra exact, personalised most cancers therapies.

This transfer comes at a crucial inflection level in drugs. The associated fee to sequence a human genome has plummeted, creating a knowledge tsunami. For hospitals and labs worldwide, the problem is not producing information, however decoding it. This ‘interpretation bottleneck’ is the one greatest barrier to delivering personalised drugs, and it could solely be solved with extremely smart software program.

“The fast tempo of personalised drugs calls for steady funding in software program innovation and deep specialization,” stated Martin Dubuc, CEO of SeqOne. “By integrating Congenica’s world-class group, we’re additional enhancing our sturdy development trajectory and talent to supply market-leading software program to prospects, skilled interpretation companies, and deepening our presence within the UK market – a worldwide chief in scientific genomics because the landmark 100,000 Genomes Undertaking.”

The acquisition comes on the heels of a interval of intense natural development for SeqOne, which has seen the corporate double its income and broaden its worldwide presence from three to over 30 international locations in simply 12 months. It additionally follows the profitable acquisition of Life & Smooth in April, which expanded the corporate’s capabilities into multi-omics and virology. This momentum, supercharged by a latest €20 million funding spherical from top-tier VCs, has enabled SeqOne to execute its technique to consolidate a fragmented market and construct the definitive software program working system for the scientific genomics revolution.

The mixed entity can have a considerably expanded international footprint:

• Serving over 160 buyer laboratories in additional than 30 international locations
• Comprising a devoted group of over 125 staff
• Enabling over 200,000 affected person genomic analyses in 2025 – a threefold enhance over 2024

SeqOne is dedicated to making sure continuity of service and help for all Congenica prospects, who will achieve entry to an expanded and built-in product portfolio. SeqOne will keep a significant UK presence on the Wellcome Sanger Institute.

“Congenica has been an instrumental companion to Genomics England, notably in advancing uncommon illness prognosis by way of their strong platform for scientific entire genome evaluation,” stated Dr. Richard Scott, Chief Govt Officer at Genomics England. “We stay up for persevering with this necessary work with the mixed experience of the SeqOne group to ship advantages for sufferers.”

“The Board of Congenica is pleased with the immense influence our expertise has had on healthcare since our inception,” stated Dr Andy Richards CBE, Chairman of Congenica. “We help this mixture with SeqOne, believing their imaginative and prescient and assets are greatest positioned to hold that legacy ahead and guarantee our modern platform continues to thrive and serve sufferers globally.”

The deal phrases will stay undisclosed.

The put up SeqOne Acquires Congenica to Lead AI Genomic Medicine first appeared on AI-Tech Park.